These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 23706679

  • 21. Meta-analysis should not be subject to selectivity and imbalance.
    Lewis LS.
    BMJ; 2015 Jun 24; 350():h3337. PubMed ID: 26108537
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S.
    Europace; 2014 Aug 24; 16(8):1137-44. PubMed ID: 24550347
    [Abstract] [Full Text] [Related]

  • 25. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 24; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 26. New anticoagulants: how to deal with treatment failure and bleeding complications.
    Kazmi RS, Lwaleed BA.
    Br J Clin Pharmacol; 2011 Oct 24; 72(4):593-603. PubMed ID: 21752066
    [Abstract] [Full Text] [Related]

  • 27. New oral anticoagulants and risks in ENT.
    Hollis S.
    Clin Otolaryngol; 2013 Aug 24; 38(4):355-7. PubMed ID: 23957550
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
    Stief TW.
    Blood Coagul Fibrinolysis; 2012 Oct 24; 23(7):619-21. PubMed ID: 22821003
    [Abstract] [Full Text] [Related]

  • 31. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E.
    MMW Fortschr Med; 2015 Jan 19; 157(1):24. PubMed ID: 25743289
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschr Med; 2012 Jan 19; 154(1):20. PubMed ID: 22641998
    [No Abstract] [Full Text] [Related]

  • 37. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar 19; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R.
    Thromb Haemost; 2014 May 05; 111(5):989-95. PubMed ID: 24352511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.